1. Home
  2. MSDL vs SUPN Comparison

MSDL vs SUPN Comparison

Compare MSDL & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MSDL
  • SUPN
  • Stock Information
  • Founded
  • MSDL 2019
  • SUPN 2005
  • Country
  • MSDL United States
  • SUPN United States
  • Employees
  • MSDL N/A
  • SUPN N/A
  • Industry
  • MSDL
  • SUPN Biotechnology: Pharmaceutical Preparations
  • Sector
  • MSDL
  • SUPN Health Care
  • Exchange
  • MSDL NYSE
  • SUPN Nasdaq
  • Market Cap
  • MSDL 1.7B
  • SUPN 1.9B
  • IPO Year
  • MSDL N/A
  • SUPN 2012
  • Fundamental
  • Price
  • MSDL $19.29
  • SUPN $31.12
  • Analyst Decision
  • MSDL Hold
  • SUPN Hold
  • Analyst Count
  • MSDL 5
  • SUPN 2
  • Target Price
  • MSDL $20.00
  • SUPN $36.00
  • AVG Volume (30 Days)
  • MSDL 408.8K
  • SUPN 628.8K
  • Earning Date
  • MSDL 01-01-0001
  • SUPN 08-05-2025
  • Dividend Yield
  • MSDL 11.41%
  • SUPN N/A
  • EPS Growth
  • MSDL N/A
  • SUPN N/A
  • EPS
  • MSDL N/A
  • SUPN 1.11
  • Revenue
  • MSDL N/A
  • SUPN $667,997,000.00
  • Revenue This Year
  • MSDL $1,597.39
  • SUPN N/A
  • Revenue Next Year
  • MSDL $15.10
  • SUPN $12.02
  • P/E Ratio
  • MSDL N/A
  • SUPN $28.03
  • Revenue Growth
  • MSDL N/A
  • SUPN 11.82
  • 52 Week Low
  • MSDL $17.59
  • SUPN $25.55
  • 52 Week High
  • MSDL $23.83
  • SUPN $40.28
  • Technical
  • Relative Strength Index (RSI)
  • MSDL 47.53
  • SUPN 39.23
  • Support Level
  • MSDL $18.85
  • SUPN $30.83
  • Resistance Level
  • MSDL $19.35
  • SUPN $32.67
  • Average True Range (ATR)
  • MSDL 0.27
  • SUPN 1.00
  • MACD
  • MSDL -0.03
  • SUPN -0.18
  • Stochastic Oscillator
  • MSDL 50.28
  • SUPN 12.89

About MSDL MORGAN STANLEY DIRECT LENDING FUND

Morgan Stanley Direct Lending Fund is a fund whose investment objective is to achieve attractive risk-adjusted returns via current income and to a lesser extent, capital appreciation by investing predominantly in directly originated senior secured term loans issued by U.S. middle-market companies backed by private equity sponsors. It invests predominantly in directly originated senior secured term loans including first lien senior secured term loans including unitranche loans and second lien senior secured term loans, with the balance of the investments expected to be in higher-yielding assets such as mezzanine debt, unsecured debt, equity investments and other opportunistic asset purchases.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Share on Social Networks: